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Heterotopic Tracheal Transplants:
Techniques and Applications
by A. J. P Klein-Szanto,*t B. C. Pal,* M. Terzaghi*
and A. C. Marchok*
Heterotopic tracheal transplants, placed subcutaneously in syngeneic rats have been extensively used in
our laboratory. The objective of these experiments was to study the toxic and/or carcinogenic effect of
several compounds on the respiratory tract mucosa. This was attained by exposing the transplants to an
intraluminal pettet containing the toxicant or carcinogen mixed with an adequate matrix (gelatin,
beeswax, stearyl alcohol, silastic, etc.). By varying the concentration ofthe test chemicals, it is possible to
study dose-response relationships, and by changing the pellet matrix, the effects ofrelease rate (dose rate)
can be analyzed. Several end points can be studied, such as histological changes in the mucociliary
epithelium, changes in mucus secretion, tumor induction and changes in the in vitro behavior of the
epithelial cells after in vivo exposure. In addition, by de-epithelializing the tracheal transplants and
reseeding them with another cell population, e.g., from previously treated cell cultures or from human
specimens and transplanting them subcutaneously in nude mice, completely new vistas on the effect of
chemicals can be opened.
Introduction
The direct application oftoxicants and/or carcinogens
to the respiratory tract epithelium by inhalation ex-
posure, intratracheal injections or pellet implantation
into the bronchus or lung has been frequently employed
in toxicology and carcinogenesis studies (1-3). Although
each of these techniques offers some advantages, with
the first two it is often difficult to determine the precise
dose delivered to each segment of exposed airway
mucosa. Furthermore, multiple exposures are usually
required to obtain the desired effect, and several
portions of the respiratory tract may be exposed to
different doses ofthe test substance. The pellet implan-
tation technique obviates these problems by exposing a
circumscribed area of respiratory mucosa to a known
quantity of test substance which diffuses out of the
pellet, either into the bronchus or into the lung. This
technique, on the other hand, is complicated and often
impairs the normal respiratory function of the treated
lung, notinfrequently leadingto premature death ofthe
animals. A model, which has the advantages of the in
loco pellet implantation technique and does not jeopar-
dize the respiratory functions of the experimental
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animal, was developed in our laboratory by transplant-
ing subcutaneously tracheas obtained from syngeneic
rats (4,5). Previous experiments by other investigators
had shown that lung parenchyma as well as tracheas
couldbetransplanted and exposedtocarcinogens (6-9).
Some of these early studies were successful in produc-
ing carcinomas after methylcholanthrene or dibenzan-
thracene exposure, and papillomas after diethylnitro-
samine exposure. The approach used in our laboratory
is to transplant tracheas subcutaneously and expose
them only after the grafts have been fully established
and revascularized. The use of several types of pellet-
matrices has permitted the controlled release of varied
total doses of test substances at a predetermined dose
rate. The combined use of fully established and
revascularizedtransplants and slowreleasepelletmatri-
ces has eliminated to a great extent, hyperacute toxic
damage to the graft and surrounding tissues, as well as
decreased the incidence ofperitracheal sarcomas, which
have been previously reported (9).
Techniques
Since most ofour own work, as well as themajority of
the experiments published to date, has been carried out
in rats, the following description ofthe transplantation
techniques will deal mainly with the procedures using
this species. Differences or variations in techniques
when using other species will be mentioned when
appropriate.KLEIN-SZANTO ET AL.
Donor Tracheas
Ten- to twelve-week-old inbred specific pathogen-free
Fischer344 rats are used as donors fortracheas. Awide
anterior thoracotomy is performed under anaesthesia
with either methoxyfluorane or sodium pentobarbital
(Fig. 1). After exposure of the anterior mediastinum
under strict aseptic conditions, the trachea is separated
from the surrounding tissues, and apolyethylene tubing
(length 20 mm, outer diameter 5 mm) is sutured to one
side ofthe trachea to preserve the original length ofthe
organ. If this step is omitted, the trachea contracts to
approximately one-half of its original length and tends
to curl. The trachea is severed below the first tracheal
ring and immediately above the carina. The laryngeal
end of the trachea is tied up with a silk suture. The
trachea is removed from the donor animal and placed in
a Petri dish containing Hank's balanced salt solution
with streptomycin and penicillin. The tracheas can be
kept in this solution for several hours without any
apparent loss in viability. Before transplantation, the
other extreme of the trachea is closed with a silk
suture. This step can be omitted without noticeable
differences because after transplantation the open end
will be closed by granulation tissue.
Recipient Animals
Rats ofthe same strainand age are used asrecipients.
They are anesthetized with methoxyfluorane, their
A
backs are shaved with electric clippers and cleansed
with 5% peracetic acid solutioninwater, and anincision,
1 to 2 cm long near the midline, is made on the dorsum,
parallel to the vertebral column between the scapulae.
With blunt dissection, two subcutaneous pouches, one
at each side of the incision, are carefully prepared to
lodge the tracheal transplants, together with their
supporting polyethylene tubing (Fig. 2). In order to
standardize the position of the tracheal transplant (tt),
the transplant is so placed that the distal end points
toward the head of the recipient animal. The wound is
then closed with surgical clips and the animal with one
tracheal transplant at each side ofthe dorsal midline is
returned to its cage. For practical purposes, usually no
more than two tracheas are transplanted per animal,
but in some cases, more transplants per animal can be
used with little inconvenience (10). This is not advisable
ifduring a long-term study the tracheal transplants are
likely to develop either tumors or extensive fibrosis,
situationswhichinterfere withtheusuallynonsynchron-
ous processes taking place in the neighboring tracheas.
Similar techniques of syngeneic tracheal transplants
have also been applied with another rat strain (10) and
otherspecies, i.e., hamsters(5,11,12), dogs (13-15), and
mice (5,16). After transplantation, the tracheal trans-
plants become revascularized in approximately 5 days.
During the first 2 days, the respiratory epithelium
becomes necrobiotic, and most cells slough off (5).
Remainingbasalcellsrapidlyrepopulatetheepithelium,
which is completely reconstituted and normal after 2
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FIGURE 1. Iransplantation procedure: (A)the wallofthe donortracheais sutured to apolyethylene tubing(arrows), and both ends are tied upby
another pair of sutures; (B) the trachea and the tubing are excised and (C) transplanted in the dorsal subcutaneous tissue of a syngeneic
recipient.
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FIGURE 2. TIacheal transplant in the subcutaneous tissue of the rat dorsum. The skin has been resected for better view.
weeks. Between 2 and 4 weeks after transplantation,
the tracheal transplant is completely revascularized,
and the epithelial lining becomes indistinguishable from
that of the host trachea (Fig. 3). It is usually at this
time that the tracheal transplant is exposed to chemical
agents. The transplant is exposed to carcinogens or
toxicants in a controlled and quantitative fashion by
insertingthe appropriate pellets (see below), containing
the test chemical, into the tracheal lumen. This is
achieved through a small incision, which can be easily
closed by either a simple suture or by using large
tantalum hemostatic clips (E. Weck Co.). Likewise, if
the exposure is to be terminated before the tracheal
transplants are removed, the pellets are extracted
through another incision at the cephalic end of the
transplant and closed again.
Materials and Vehicles for
Intratracheal Pellets
The selection of the pellet vehicles or matrices
depends on the nature of the materials to be released
from the pellet and on the desired rate of release. In
most cases, a long exposure of the tracheal mucosa to
constant concentrations of chemicals and in conse-
quence a slow release of the test chemical from the
pellet is desired. Tracheal transplants can be exposed to
two types oftest agents which require different vehicles
and pellet manufacturing techniques: lipophilic sub-
stances, such aspolycyclic aromatic hydrocarbons (PAH)
and 12-0-tetradecanoyl-phorbol 13-acetate (TPA), which
are incorporated into nondegradable matrices such as
beeswax (17), silastic (18) or lycra fibers (12) and poorly
soluble particles or fibers, such as nickel subsulfide,
asbestos or arsenic trioxide embedded into degradable
vehicles such as gelatin. This latter approach implies
relatively short exposure times and an abrupt release of
the test agent since gelatin dissolves rapidly at body
temperature. Alternative matrices for poorly soluble
particles and fibers which enable longer exposure times
are under development.
Technology of Pellet Production
The rate ofrelease ofthe test agent from the pellets
depends mainly on the nature of the pellet matrix.
Materials for pellet matrices must meet the following
criteria: should be nontoxic; should notinteractwith the
carcinogen/toxicant; should be easily fabricated into
solid cylindrical pellets (14 mm x 1.4 mm diameter for
rattrachea) atlowtemperaturestoavoidanydecomposi-
tion of the test chemical. Release from such monolithic
cylindrical pellets containingthe dispersed test agent is
controlled by the rate of diffusion of the chemical
through the pellet matrix to the boundary surface as
proposed by Higuchi (19). Invariably, an initial high
release rate (burst effect) occurs (20) until the equilib-
rium is reached and the release takes place in a
controlled fashion.
LipidMatrices. Beeswax, stearyl alcohol and choles-
terol have been employed in our laboratory for slow
release of PAH and TPA. Relatively low-melting (up to
150°C) matrices containing the dissolved/dispersed
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FIGURE 3. Normal mucociliary epithelium lining the tracheal lumen 7 weeks after transplantation. (Tbluidine blue, Epon, x 360.)
agent can be fabricated most conveniently in the pellet
maker (4) (Fig. 4). The test agent and lipid substance is
put into aglass scintillation vial and placed in the recess
ofan aluminum block which is heated on a thermostati-
cally controlled electric heater. The block should be
drilled for accommodating a thermometer to monitor
the temperature. Heaters (Cole Palmer Instruments)
equipped with immersion thermistor probes have been
found satisfactory. These probes are placed in another
cavity drilled in the block. Occasionally, it is difficult to
push the pellets out ofthe mold by using the push pin.
In suchi a situation, the mold should be reheated by
placing in a water bath to a temperature which facili-
tates extrusion.
The pellet maker works best if the dispersed test
agent does not show any tendency to settle. If settling
occurs, the matrix is melted in a hot mortar and the
agent is mixed with the matrix thoroughly, using the
pestle and mortar and allowing it to cool until it
solidifies. The mix is scraped out from the mortar and
packed into a cylindrical mold of a sodium press (No. 1
Greenerd Arbor Press, Fisher Scientific Co.). This
mold is fitted with a die with a 1.5 mm diameter orifice,
through which the pellets can be extruded by manually
driving a plunger fitted with a rack and pinion
mechanism. The mold is warmed to a suitable tempera-
ture (below the melting point ofthe mix) and extruded
out quickly. The extruded material is cut into proper
lengths by using a channeled Teflon block very much
like a carpenter's miter box.
Pellets Containing PAH. Controlled release ofpoly-
cyclic hydrocarbons like benzo(a)pyrene (BaP), 7,12-
dimethylbenz(a)anthracene(DMBA)frombeeswaxalone
and from cholesterol-beeswax matrices has been re-
ported earlier (17). The presence of cholesterol in a
beeswax-cholesterol matrix retards the release ofPAH
in direct proportion to the percentage of cholesterol
present. The use of cholesterol of highest purity is
essential, and commercially available highest purity
cholesterol (Eastman Kodak) should be purifiecrfurther
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FIGURE 4. Schematic representation of the pellet maker used for
manufacturing carcinogen-containing beeswax or gelatin pellets.
From Griesemer (4).
by the method of Fieser (21) and checked for purity by
gas chromatography on a 3% SP-2250 column (Supelco).
We have recently found an undesirably high back-
ground in the epithelial focus (EF) assay (22, M.
Terzaghi, unpublished data) as well as the induction of
stratified metaplasias after exposing tracheal trans-
plants to cholesterol. In addition, some cholesterol
autoxidation products have been found to be mutagenic
(23). Stearyl alcohol has been found to be an acceptable
substitute for cholesterol since it shows very low
background inthe EF assay. The release rates ofDMBA
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from beeswax-stearyl alcohol (1:9) and beeswax-
cholesterol (1:9) matrices are shown in Figure 5. The
use ofbeeswaxis necessary as abinder, since pellets are
extremely fragile and difficult to handle when made
out of cholesterol or stearyl alcohol alone. A typical
preparation of stearyl alcohol-beeswax DMBA pellets
is described below.
Weighed amounts of DMBA (Eastman Kodak), puri-
fied by crystallization from ethanol as described pre-
viously (17), and stearyl alcohol, and beeswax (purified
byfiltration through asteam-heatedfrittedglassfunnel)
are heated together in a scintillation vial placed in an
aluminum block until a clear melt is formed (65°C). The
hot melt is transferred into the well ofthe pellet maker
heated to the same temperature and the matching half
is placed on the well, forcing the melt to flow into the
holes where, following rapid chilling, cylindrical pellets
are formed. A copper block (7.5 cm x 7.5 cm diameter)
chilled in ice was found to be very convenient for
cooling the pellet maker.
In order to directly assay the amount ofDMBA in the
pellets, a weighed aliquot ofthe pellet is dissolved in 10
mL of benzene in a capped scintillation counting vial
placed in a shaker water bath at 37°C. The absorbance
at 301 nm is read after appropriate dilution, and the
concentration of the DMBA determined using a molar
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FIGURE 5. Release rates of DMBA from several pellet matrices.
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extinction coefficient of 78,700. Neither beeswax nor
stearyl alcohol or benzene shows any appreciable
absorbance at this wavelength. The pellets are best
stored in a deep-freeze under nitrogen in the absence of
light.
If a slower release rate is desired, DMBA may be
absorbed on carbon particles and dispersed in the
stearyl alcohol-beeswax (9:1) matrix and made into
pellets using the sodium press. Carbon particles
(Barnaby Chaney) are passed through sieve #200 and
sieve #325 and the particles retained on the latter are
used.
DMBA-carbon (1:9) is prepared as follows. Carbon
particles (9.0 g) are added with stirring to a hot solution
of DMBA (1.1 g) in acetone (160 mL) in a beaker. The
acetone is allowed to evaporate in the hood at room
temperature. All of the dried, caked mixture from the
wall of the beaker is scraped down, and the side ofthe
beakerrinsed with 3 mL acetone. The mixture is heated
gently with constant stirring and scraping. After all of
the acetone has evaporated, the mixture is heated to
about 145°C, with continued scraping and stirring. The
mixture becomes dry and powdery. The final product is
cooled in a desiccator. To assay the amount ofDMBA in
the mixture, samples are extracted in a double thick-
ness cellulose thimble (Whatman 1317-403) placed in a
Soxhlet apparatus withbenzene. Ultraviolet absorption
spectrum measurements showthat DMBAisnotdecom-
posed by this treatment and the absorption of DMBA
into carbon is uniform. Weighed amounts of DMBA-
carbon are mixed together with stearyl alcohol and
beeswax using ahot mortar and pestle, transferred into
the mold, heated to 58°C, and extruded into pellets
using the sodium press. The uniformity of the pellets
can be checked by assaying for DMBA content. A
typical in vivo release rate of carbon-adsorbed DMBA
from these pellets is shown in Figure 5.
Pellets Containing 12-0-Tetradecanoylphorbol 13-
Acetate (TPA). Beeswax can be used as a matrix and
the TPA pellets can be conveniently made using the
pellet maker. Since the molar extinction ofTPAis low, it
is advisable to use radioassay by incorporating [3H]TPA
for quantitative determinations of TPA release. An
aliquot can be counted directly in a toluene-based
scintillation fluid. Figure 6 shows the release pattern
from a beeswax pellet containing 100 ,ug TPA.
Water-Soluble and Degradable Matrices. Twelve
percent aqueous gelatin has been successfully used as a
vehicle for rapid release ofpoorly soluble particles and
fibers, such as Ni3S2, asbestos, carbon particles and
glass fibers. It has also been used for the rapid release
(and in consequence forshort, acute exposures) ofPAH.
Using a warm pestle and mortar, the agent is mixed
thoroughly with the gelatin solution and allowed to cool
to room temperature while triturating until the mix
solidifies. It is then transferred to a scintillation count-
ing vial and heated in an aluminum block to 30°C and
79
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Evaluation ofIntratracheal Content. The type of
|400 Ig [3H] TPA-BEESWAX IN VIVO1 intratracheal contents, as seen by naked eye, can point
to the nature of the changes taking place in the
epithelium, e.g., keratin can be recognized as semisolid
white clumpy masses, and is indicative of squamous
metaplasia and/or neoplasia, purulent secretion will
signify inflammation and large quantities of mucous
secretion will indicate hypertrophy of the secretory
epithelium.
Biochemical analyses of the tracheal secretions have
characterized the normal mucin fraction of the rat
tracheal transplants (24). The purified mucin from the
transplant contained high molecular weight glycopro-
tein with acarbohydrate and amino acid content charac-
teristic ofmucins. It is well known that similar fractions
obtained from tracheal organ cultures undergo changes
when exposed to an altered environment such as
vitamin A-deficient media (25). Changes in the mucin
secretion characteristics have also been described in
neoplastic epithelial cell lines derived from carcinogen-
treated tracheal epithelium (26). Mucous secretions
from tracheal transplants could serve as an ideal model
/ l l l l for biochemical studies of in vivo alterations after
0 4 2 3 4 5 exposure to toxicants or carcinogens. The potential 2IME (weeks) value of such a nondestructive analysis can not be
TIME(weeks) overstated, and this model offers the possibility of
performing long-term studies and obtaining multiple
Release of TPA from beeswax pellets. secretion samples from the same transplanted organs.
Another type ofnondestructive analysis, namely exfoli-
ate cytology, can be performed easily in a longitudinal
itopelletsusing thepellet maker. Thepellets are study of the effects of chemicals on the tracheal
ried on plastic Petri dishes placed inside a epithelium. Although this possibility has not been
i desiccator over sodium hydroxide pellets. The exploited, all the techniques are available (27) and the
ellets are then assayed for uniformity. In most sampling procedures, which should produce minimum
the pellet is weighed, stirred in water, and possible damage to the tracheal transplant, could be
through a tared millipore filter. The filter is easily developed.
rhly washed with water, dried, andweighed. The Histological Study ofTracheal Transplants. His-
,ration of agent in gelatin should not vary more tological observation of tissue sections is the most
5%. frequently employed method for evaluating the state of
minary data suggest that particulate and fibrous the epithelium and wall ofthe tracheal transplant. Most
Ll can be released in a continuous slow fashion studies have relied on routine paraffin embedding, and
earyl alcohol-beeswax (9:1 ratio), orpolyglycolic some have preferred the higher resolution provided by
[lets(material usedinresorbablesurgicalsutures; plastic embedding (28-31). Several papers have dealt
tact with body fluids it slowly degrades by with the ultrastructural characteristics of the normal
rsis). These matrices gradually release the em- and altered epithelium (28,29).
particulate material, which then comes in con- The most critical issue when studying the distribu-
th the tracheal epithelium. tion and frequency of lesions in the tracheal transplant
is the sampling of each trachea. In most studies, the
ation of Effects tracheas were cuttransversally into rings 1 to 1.5 mm
thick. The tracheal pieces are kept in proper order
a short- or long-term exposure to chemicals, during dehydration and embedding by passing a silk
macroscopic evaluation ofthetransplanted organ thread through the surrounding connective tissue of
real significant alterations, such as paratracheal each ring. The tissues were embedded maintaining
atracheal cysts or aneurismal dilatations (fre- the rings in proper order and orientation. Three to
seen after destruction of part of the wall and four sections 50p,m apart were then performed, thus
uent migration of epithelium to an extraluminal further enlarging the sampled area. An alternative
a), solid tumors, atrophy and fibrosis, hypertro- method, permitting an ample visualization of the lumi-
e to accumulation of secretion, etc. nal epithelium using only one or two blocks of tissue is
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the so-called "Swiss roll," in which the trachea is cut
frontally in two pieces, then rolled cephalocaudally, and
tied with thread to keep it in this position (32). Another
method which could permit a selective sampling of
tracheal regions has been used for detecting squamous
metaplasias of the larynx. This involves staining the
whole organ (fixed or unfixed) in either pyronin (33) or
alcian blue-phloxine (34) and then processing for histol-
ogy only the positively stained areas. This method can
be used for the detection of squamous metaplasias in
the tracheal transplants, and it seems especially indi-
cated when using tracheas from large animals.
In Vitro Studies of in Vivo-Exposed Cell Popula-
tions. In vitro techniques offer new possiblities for
the study of sequential changes presumed to occur
duringthe invivo development ofneoplasia. It has been
shown that shortly after carcinogen exposure of tra-
chealtransplants, epithelial cells which have amarkedly
increased growth capacity can be isolated from the
tracheal mucosa (22,35). A series of techniques collec-
tively referred to as the EF assay has been devised to
quantitate in vitro the emergence ofcarcinogen-altered
and neoplastic cell populations in vivo in tracheas
exposed to carcinogen. A detailed protocol has been
previously described (22). Briefly, the EF assay entails
the following sequential phases. Heterotopic tracheal
transplants are exposed to PAH as described above. At
various time intervals after initiation of exposure,
beginning prior to the development of frank neoplastic
or even before the appearance of preneoplastic lesions,
tracheal transplants are removed from host animals.
Luminal epithelial cells are dispersed enzymatically and
seeded into tissue culture dishes in order to establish
primary cultures, the number of EF (proliferating
epithelial cell foci) per dish is scored. When isolated,
each EF contains roughly 5 x 104 cells. They are
removed from the primary dish enzymatically and each
EF seeded into a separate secondary culture dish. The
fraction of EF which can be subcultured two or more
times is noted. All subculturable EF (EF.) are tested
for the capacity to grow in soft agarose. In this system,
the capacity to grow in soft agarose has beenfound to be
well correlated with the capacity of a cell population to
yield tumors when inoculated IM into immunosup-
pressed rats (35,36).
The EF assay has made it possible to monitor the
development in vivo ofcell compartments endowed with
different proliferative and neoplastic potentials in vitro.
Epithelia from normal noncarcinogen-exposed tracheas
yield few EF in primary culture. Epithelia from
carcinogen-exposed tracheas yield 10 to 100 times more
EF than control cultures. The capacity of EF to be
subcultured (EF.) and the capacity of EFs to grow in
soft agarose(EF., ag+) appeartoreflect the severityof
carcinogen-induced changes in tracheal epithelium. The
frequency of EFs and EFs, ag+ populations increase
both with carcinogen dose and increased time after
exposure (22,37).
Applications
Most studies employingthe trachealtransplant model
have dealt with the induction ofneoplastic and preneo-
plastic lesions after in vivo exposure to polycyclic
aromatic hydrocarbons. This model makes possible
other studies in the field of toxicology and carcino-
genesis. Some ofthe most recent applications are listed
and briefly described below.
Early Effects ofToxicants and Carcinogens
The aim of these studies is to evaluate the toxic
effects of several chemicals on the tracheal tissues
(especially the epithelium) over an 8-week period. Most
of the chemicals thus far evaluated in our laboratory
were known or suspected carcinogens or closely related
substances. Topping et al. (38) compared the acute
effects of seven PAH on the tracheal epithelium by
exposing the tracheal transplant with beeswax pellets
containing 1 mg of pyrene (P), benzo(e)pyrene (BeP),
anthracene (A), benz(a)anthracene (BaA), dibenz(ac)-
anthracene (DBacA), benzo(a)pyrene (BaP) ordimethyl-
benz(a)anthracene (DMBA). The release of PAH from
the pellets was determined by ultraviolet spectro-
photometry at 3 days, 1, 2, 4 and 8 weeks. All PAHs
were released continuously during the 8-week period.
Approximately, 1 mg of PAH was released from the
pellets containing P, BeP, BaP and A, whereas only
approximately 500 ,ug was released after 8 weeks from
the pellets containingthe other PAHs. The toxic effects
ontherespiratoryepitheliumwereevaluatedbymeasur-
ing the percentage of luminal surface occupied by
normal, hyperplastic and metaplastic epithelia (Fig. 7).
Although all compounds proved to be toxic for the
tracheal epithelium, the degree ofalterations induced in
the tracheal transplants was variable, (i.e., the potent
carcinogens (BaP and DMBA) showing a maximum of
early toxic effects and the noncarcinogens or weak
carcinogens (BeP, A, P) inducing less severe changes or
short duration. A similarstudywasundertaken inorder
to evaluate the effects of chrysotile A and crocidolite
asbestos in gelatin pellets (39). Both substances pro-
duced intense dose-dependent inflammatory reaction
and epithelial alteration over a period of 4 weeks. The
effect ofcrocidolite lasted somewhat longer than that of
chrysotile A. Another carcinogen which induced exten-
sive early toxic alterations was nickel subsulfide (40).
Other particulates have been tested in the same model
in our laboratory, i.e., arsenic trioxide, glass fibers, and
charcoal particles. All these induced a weak or no
response (Klein-Szanto et al., unpublished data). Al-
though there are many complicated and interacting
factors involved, (e.g., dose, dose rate, schedule of
administration, etc.), these experiments indicate that
strong carcinogens are usually very irritant and inflam-
matogenic forthe respiratory tract epithelium, and that
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FIGURE 7. Extent and type of epithelial changes induced by various polycyclic hydrocarbons. The estimated percent tracheal surface area
occupied by various epithelial morphologies is shown: (-) normal appearing epithelium; (-) hyperplasia; (--) transitional epithelium;
(... .) squamous metaplasia. Values are based on six tracheas per time point. Each trachea received 1 mg of PCH incorporated in
beeswax. Control tracheas received pellets made of beeswax only. The intensity of the epithelial change is indicated as (v) mild; (0)
moderate; (A) severe. From Ibpping et al. (38).
weak or noncarcinogenic related substances tend to
induce a lesser reaction.
TumorInduction and CancerMorphogenesis
The advantage ofthe tracheal transplant model, i.e.,
knowing the precise quantity ofcarcinogen delivered to
the tracheal mucosa, the exact period of time during
which the mucosa is exposed to the carcinogenic agent,
and the uniformity ofexposure ofthe whole organ, have
been exploited in several carcinogenesis studies. Using
rat tracheal transplants continuously exposed to vary-
ing amounts ofbenzo(a)pyrene or 7,12-dimethylbenz(a)-
anthracene in beeswax pellets, investigators in our
laboratory have detected acleardose-dependency inthe
tumor induction capacities ofthese PAHs (41,42) (Table
1). Although more than 90% of the carcinogen is
released in 4 weeks from beeswax pellets containing
less than 200 ,ug DMBA, a clear decrease inthe number
of induced tumors was observed when pellets were
removed after4 weeks ofexposure (43). Only 20% ofthe
tracheal transplants presented carcinomas, as opposed
to approximately 60% when the DMBA containing
pellet was left in for the whole duration of the
experiment. These results are very similar to those
obtained after a 4-week exposure to 200 ,ug DMBA-
containing pellets, followed by a continuous exposure to
100 ,ug TPA. In this latter case, in which a two-stage
carcinogenesis protocol, similar to the one employed in
skin carcinogenesis studies (44) was employed, the
percentage of induced neoplasm was 70 (45). From
these experiments, it became obvious that the total
time of exposure to PAH was at least as important as
the total dose employed, and that a promotion-like
effect elicited by either very small amounts ofPAHs or
by known promoters such as TPA orputative promoters
like asbestos (46) is a probable pathogenic mechanism
in respiratory carcinogenesis.
Usingsimilarexperimentalconditions, wehave exten-
sively studied the morphogenesis of tracheal epithelial
neoplasia, a detailed account of which is outside the
scope of this chapter. The reader is referred to several
recent reports on this subject (43,47). Briefly, the most
interesting findings have been the reversibility of the
early generalized toxic epithelial alterations induced by
PAH (47) (Fig. 8), and the later appearance of focal
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Table 1. Tumor development induced by BaP and DMBA in
tracheal transplants.
PAH Total tumors/number
PAH dose, FLg of tracheal transplants
BaPa 45 0/10
300 1/14
900 2/12
1250 7/13
1740 15/10
2160 18/12
2490 40/52
DMBAb 10 0/24
40 0/24
115 7/24
210 23/36
325 11/11
1240 12/12
a From Nettesheim et al. (42); includes all types of epithelial
neoplasms.
b From Griesemer et al. (41); includes only carcinomas.
metaplastic-dysplastic lesions of varying degrees of
atypia which usually precede the appearance of neo-
plasms (Fig. 9) (43). The number and degree ofseverity
of these lesions also seems to be dose dependent. Of
particular interest was the fact that many of the focal
lesions regress after they reach a peak incidence, thus
demonstrating that these lesions are not obligatory
preneoplastic alterations.
Other studies have demonstrated a continuum of
changes from the mildest to the more severe preneo-
plastic alterations. Quantitative techniques demon-
strated increasing nucleus-cytoplasm ratios, 3H-thymi-
dine labelingindices and number ofdarkepithelialcells,
indicating increasing degrees of cell proliferation and
altered cellular maturation (31).
Other studies employing rat tracheal transplants
have demonstrated the carcinogenic and promoting
effects of asbestos (39,46), nickel subsulfide (40) and
chromium carbonyl (10). The carcinogenic effects of
PAH have also been studied in hamsters (5,11,12), mice
(5,16) and dogs (13-15).
Repopulation of Tracheal Transplants with
Isolated Cell Populations
Itisoftendifficulttostudythegrowthand differentia-
tion of cultured or isolated normal or preneoplastic
epithelial cells when transferred into an in vivo
situation. Followingsubcutaneousorintramuscularinoc-
ulationtheyfrequentlydonotsurviveand/orproliferate,
thus making it difficult to retrieve themformorphologic
evaluation. In order to be able to study sequential
morphologic changes occurring in vivo in multiple
aliquots derived from the same original cell population,
we developed a technique which involves the "in vivo
culture" ofnormal or preneoplastic cells on de-epitheli-
atized tracheal stroma. The de-epithelialized stroma
provides those factors required for the survival and
differentiation of normal and preneoplastic epithelial
FIGURE 8. Generalized stratified metaplasia, after2 weeks exposure
to 200 ,ug DMBA. The surface cells contain Alcian Blue-positive
material, indicative of the presence of acid mucosubstances.
(PAS-Alcian Blue, pH 2.6, x 240.)
cells which are apparently lacking in the intramuscular
or subcutaneous environment. The procedures have
been published in detail (36,48). Briefly, fresh suspen-
sions ofnormal respiratory tract epithelium or cultured
epithelial cells originating from tracheas previously
exposed to PAH in vivo are inoculated into the lumina
of de-epithelialized tracheas. De-epithelialization is
achieved by enzyme digestion (36) orbydevitalization of
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of cell inoculation and implantation. Once inoculated
tracheas are implanted into suitable hosts, approxi-
mately 2 to 3 weeks are required for the complete
regeneration of a tracheal epithelium. When normal
epithelial cells havebeeninoculated, mucociliary epithe-
lium with occasional areas of simple or stratified squa-
mous epithelium is seen. Inoculated preneoplastic cell
lines give rise to a relatively homogeneous epithelia of
either an atrophic, cuboidal, or stratified squamous
nature, exhibiting various degrees of atypia (Fig. 10).
After variable lengths oftime during which the epithe-
lium remains remarkably stable, some of the preneo-
plastic cell lines give rise in vivo to cell subpopulations
which invade the tracheal wall. Tracheas inoculated
with neoplastic cell lines are rapidly repopulated with
what initially appears to be a stratified squamous
epithelium exhibiting moderate to marked atypia.
Within 1 to 4 weeks, one sees a rapid disorganization of
this epithelium with marked cell proliferation and
invasion of the transplant wall.
In general, the epithelial morphologies observed in
these studies are highly reminiscent ofvarious neoplas-
tic and preneoplastic lesions observed following expo-
sure ofintact rat tracheas to PAH. This "in vivo culture
system" appears to be well suited to the study of the
growthand differentiation characteristics ofcarcinogen-
altered or preneoplastic cell populations. This is other-
wise not readily accomplished, since nonneoplastic cells
when inoculated subcutaneously or intramuscularly
either do not survive or do not proliferate and are thus
often difficult to retrieve for morphologic evaluation.
This in vivo culture system has also been further
developed for purposes of investigating differences in
the stromal requirements, for growth and differentia-
tion in vivo, or normal and PAH altered cell populations
(36). For normal tracheal epithelial cell survival and
maintenance of mucociliary differentiation in vivo, an
intact but not necessarily viable stroma (tracheal,
intestinal, esophageal, or bladder) is required. Preneo-
plastic and neoplastic cells will survive and differentiate
in vivo on all substrates including, for example, dacron
mesh which will not support normal cell growth and
differentiation.
FIGURE 9. Focal atypical lesions observed after24weeks exposure to
200 ,ug DMBA. (Tbluidine blue, Epon, x 300.)
the whole organ by repeated freeze-thawing (48). The
tracheas are then transplanted into the dorsal subcuta-
neous tissue of host rats or nude mice. Immunocompe-
tent hosts (rats) can be used for the growth of normal
rat tracheal epithelial cells. Immunodeficient hosts
(e.g., irradiated nude mice or thymectomized, irradi-
ated rats) are generally required for long-term mainte-
nance of preneoplastic and neoplastic cell lines. In the
latter case, if immunocompetent hosts are used, the
established tracheal lining rejected within 1 to 4 weeks
Repopulation of Tracheal Transplants with
Human Epithelial Cells
Usingthe same repopulationtechniques, it is possible
to reconstitute a normal human respiratory epithelium
in previously de-epithelialized rat tracheas transplanted
sc in nude mice (14). Using cells derived directly from
tissues obtained at autopsy, we have been able to
establish up to 10 reconstituted tracheal transplants
from each stillborn fetus. Within 2 to 4 weeks of cell
inoculation and transplantation, these tracheas are fully
repopulated with a normal appearing human respira-
tory epithelium. This epithelium is enzymatically har-
vested and inoculated into 30 to 50 new de-epithelialized
rat tracheas and transplanted subcutaneously into a
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new series of host animals. In this way, with each
sequential in vivo passage of human epithelial cells a
population amplification factor of3 to 5 is achieved. This
procedure can be repeated at least four times (49).
Preliminary experiments involvingexposureofreconsti-
tuted human respiratory epithelium to DMBA suggest
that studies similar to those carried out with exposed
rat tracheal epithelium can also be carried out with
human respiratory epithelium (50).
Research supportedbythe NationalCancerInstitute (YO1-CP90211
and Y01-CP90207), the National Institute of Environmental Health
Sciences, and the Office ofHealth and Environmental Research, U.S.
Department ofEnergy, under contract W-7405-eng-26 with the Union
Carbide Corporation and by Public Service Grant CA 35552 awarded
by NCI, DHHS.
REFERENCES
1. Nettesheim, P, and Griesemer, R. A. Experimental models for
studies ofrespiratory tract carcinogenesis. In: Pathogenesis and
Therapy of Lung Cancer (C. Harris, Ed.), Lung Biology in
Health and Disease (C. Lenfant, Ed.), Vol. 10, Marcel Dekker
Inc., New York, 1978, pp. 75-188.
2. Nettesheim, R, Klein-Szanto, A. J. R, Marchok, A. C., Steele, V
E., Terzaghi, M., and Topping, D. C. Studies of neoplastic
development in respiratory tract epithelium. Arch. Pathol. Lab.
Med. 105: 1-10 (1981).
3. Nettesheim, P, and Schreiber, H. Advances in experimental lung
cancer research. In: Handbuch der Allgemeinen Pathologie
(H. W Altmann, F. Buchner and H. Cottier, Eds.) Vol. 6.
Springer-Verlag, Berlin, 1975, pp. 603-691.
4. Griesemer, R. A., Kendrick, J., and Nettesheim, PF Tracheal
grafts. In: Experimental Lung Cancer: Carcinogenesis and
Bioassays (E. Karbe and J. F. Park, Eds.), Springer-Verlag,
Berlin, 1974, pp. 539-547.
5. Kendrick, J., Nettesheim, P, and Hammons, A. S. Tumor
induction in tracheal grafts: a new experimental model for
respiratory carcinogenesis studies. J. Natl. Cancer Inst. 52:
1317-1325 (1974).
6. Crocker, T. T., and Nielsen, B. I. Organ culture followed by
grafting of rat tracheas exposed to hydrocarbons. Proc. Am.
Assoc. Cancer Res. 7: 16 (1966).
7. Dontenwill, W Experimentelle Untersuchungen zur Genese des
Lungens-carcinoma. Arzneim. Forsch. 14: 774-780 (1964).
8. Smith, W E. The tissue transplant technique as a means of
testing materials for carcinogenic action. Cancer Res. 9: 712-723
(1949).
9. Smith, W E., Yazdi, E., and Miller, L. Carcinogenesis in
pulmonary epithelia in mice on different levels of vitamin A.
Environ. Res. 5: 152-163 (1973).
10. Lane, B. R, andMass, M. J. Carcinogenicityandcocarcinogenicity
ofchromium carbonyl in heterotopic tracheal grafts. Cancer Res.
37: 1476-1479 (1977).
11. Craighead, J. E., and Mossman, B. T. Carcinoma induction by
3-methylcholanthrene in hamster tracheal tissue implanted in
syngeneic animals. Prog. Exptl. Tumor Res. 24: 48-60 (1979).
12. Mossman, B. T., and Craighead, J. E. Induction of neoplasms in
hamster tracheal grafts with 3-methylcholanthrene-coated lycra
fibers. Cancer Res. 38: 3717-3722 (1978).
13. Kobayashi, N., Kanisawa, M., Okamoto, T., Okita, M., and
Katsuki, H. Sequential cytologic study of the development of
squamous cell carcinoma induced in subcutaneously implanted
bronchial autograft of dog. Acta Cytol. 22: 99-104 (1978).
14. Kobayashi, N., Okita, M., Yarita, T., Hanzawa, S., Okamoto, T.,
and Katsuki, H. A method for experimental induction of
bronchogenic carcinoma in subcutaneously implanted bronchial86 KLEIN-SZANTO ET AL.
autograft in dogs, J. Thorac. Cardiovasc. Surg. 75: 434-442
(1978).
15. Kobayashi, N., Okamoto, T., Yarita, T., Tanaka, T., Okita, M.,
and Katsuki, H. Cancer induction in subcutaneously implanted
bronchial autografts of a dog by 3-methylcholanthrene. Gann 67:
611-615 (1976).
16. Ebenstein, P, Kinder, B., Bankole, D. O., Richards, F F, and
Armstrong, M. Y K. Expression of endogenous xenotropic
retrovirus by methylcholanthrene-induced squamous cell carci-
noma of the mouse respiratory tract. J. Exptl. Med. 150:
1567-1570 (1979).
17. Pal, B. C., Topping, D. C., Griesemer, R. A., Nelson, F R., and
Nettesheim, P Development ofa system for controlled release of
benzo(a)pyrene, 7,12-dimethylbenz(a)anthracene, and phorbol es-
ter for tumor induction in heterotopic tracheal grafts. Cancer
Res. 38: 1376-1383 (1978).
18. Shors, E. C., Fu, P C., Matsumura, K., Cohen, A., and Benfield,
J. R. Sustained release of benzo(a)pyrene from silicone polymer
into the tracheobronchial tree ofhamsters and dogs. Cancer Res.
40: 2288-2294 (1980).
19. Higuchi, T. Rate ofrelease ofmedicaments from ointment bases
containing drugs in suspension. J. Pharm. Sci. 52: 1145-1150
(1963).
20. Baker, R. W, and Londsdale, H. K. Controlled release: mecha-
nisms and rates. In: Controlled Release of Biologically Active
Agents (A. C. Tanguary and R. E. Lacy, Eds.), Plenum Press,
NY, 1973, pp. 15-71.
21. Fieser, L. F Cholesterol, A5-cholesten-3-one, and A4-cholesten-
3-one. Org. Syn. Coll. 4: 195 (1963).
22. Terzaghi, M., and Nettesheim, P Dynamics ofneoplastic develop-
ment in carcinogen-exposed tracheal mucosa. Cancer Res. 39:
4003-4010 (1979).
23. Smith, L. L., Smart, V B., and Ansari, G. A. S. Mutagenic
cholesterol preparations. Mutat. Res. 68: 23-30 (1979).
24. Clark, J. N., and Marchok, A. C. Characterization of mucin
isolated from rat tracheal transplants. Biochim. Biophys. Acta
588: 357-367 (1979).
25. Clark, J. N., Klein-Szanto, A. J. P, Pine, A. H., Stephenson, K.
B., and Marchok, A. C. Reestablishment of a mucociliary
epithelium in tracheal organ cultures exposed to retinyl acetate: a
biochemical and morphometric study Eur. J. Cell Biol. 21:
261-268 (1980).
26. Marchok, A. C., Clark, J. N., and Klein-Szanto, A. J. P
Modulation of growth, differentiation, and mucous glycoprotein
synthesis by retinyl acetate in cloned carcinoma cell lines. J.
Natl. Cancer Inst. 66: 1165-1174 (1981).
27. Schreiber, H. Cytopathology in pathogenesis and therapy oflung
cancer. In: LungBiologyin Health and Disease (C. Lenfant, Ed.),
Vol. 10. Marcel Dekker, New York, 1978, p. 521.
28. Klein-Szanto, A. J. P, Tbpping, D. C., Heckman, C. A., and
Nettesheim, P Ultrastructural characteristics of carcinogen-
induced dysplastic changes in trachealepithelium. Am. J. Pathol.
98: 83-100 (1980).
29. Klein-Szanto, A. J. P, Tbpping, D. C., Heckman, C. A., and
Nettesheim, P Ultrastructural characteristics of carcinogen-
induced non-dysplastic changes in tracheal epithelium. Am J.
Pathol. 98: 61-82 (1980).
30. Klein-Szanto, A. J. P, Nettesheim, P, Pine, A., and Martin, D.
Distribution and ultrastructural characteristics of dark cells in
squamous metaplasias of the respiratory tract epithelium. Am.
J. Pathol. 103: 263-270 (1981).
31. Klein-Szanto, A. J. P, Nettesheim, R, Tbpping, D. C., and Olson,
A. C. Quantitative analysis of disturbed cell maturation in
dysplastic lesions oftherespiratory tractepithelium. Carcinogen-
esis 1: 1007-1016 (1980).
32. Knudtson, K. P A method of study of squamous metaplasia,
atypical change, an early bronchogenic carcinoma ofthe bronchial
mucosa in smokers and nonsmokers. Cancer 9: 84-85 (1956).
33. Watt, J., Gregory, I., and Stell, P M. A simple method for the
post-mortemdemonstrationofsquamousmetaplasiainthelarynx.
J. Pathol. 104: 149-154 (1970).
34. Watt, J., Gregory, I., and Stell, P M. An alcian-blue phloxine
method for the gross demonstrations of squamous metaplasia in
the larynx. J. Pathol. 116: 31-36 (1975).
35. Marchok, A. C., Rhoton, J. C., and Nettesheim, P In vitro
development ofoncogenicity in celllines established from tracheal
epitheliumpreexposedinvivoto7,12-dimethylbenz(a)anthracene.
Cancer Res. 38: 2030-2037 (1978).
36. Terzaghi, M., Nettesheim, P, and Williams, M. L. Repopulation
of denuded tracheal grafts with normal, preneoplastic and neo-
plastic epithelial cell populations. Cancer Res. 38: 4546-4553
(1978).
37. Terzaghi, M., Nettesheim, P, and Riester, L. Effect ofcarcinogen
dose on dynamics of neoplastic development on rat tracheal
epithelium. Cancer Res. 42: 4511-4518 (1982).
38. Topping, D. C., Pal, B. C., Martin, D. H., Nelson, F R., and
Nettesheim, P. Pathologic changes induced in respiratory tract
mucosa by polycyclic hydrocarbons of differing carcinogenic
activity. Am. J. Pathol. 93: 311-324 (1978).
39. Tbpping, D. C., Nettesheim, P, and Martin, D. H. Toxic and
tumorigenic effects of asbestos on tracheal mucosa. J. Environ.
Pathol. Toxicol. 3: 261-275 (1980).
40. Yarita, T., and Nettesheim, P Carcinogenicity ofnickel subsulfide
for respiratory tract mucosa. Cancer Res. 38: 3140-3145 (1978).
41. Griesemer, R. A., Nettesheim, P, Martin, D. H., and Caton, J.
E., Jr. Quantitative exposure of grafted rat tracheas to 7,12-di-
methylbenz(a)anthracene. Cancer Res. 37: 1266-1271 (1977).
42. Nettesheim, P, Griesemer, R. A., Martin, D. H., and Caton, J.
E., Jr. Induction ofpreneoplastic and neoplastic lesions in grafted
rattracheas continuously exposed tobenzo(a)pyrene. Cancer Res.
37: 1272-1278 (1977).
43. Ibpping, D. C., Griesemer, R. A., and Nettesheim, P Develop-
ment and fate of focal epithelial lesions in tracheal mucosa
following carcinogen exposure. Cancer Res. 39: 4829-4837 (1978).
44. Boutwell, R. K. Function and mechanisms of promoters of
carcinogenesis. CRC Crit. Rev. Toxicol. 2: 419-443 (1974).
45. Topping, D. C., and Nettesheim, P Promotion-like enhancement
of tracheal carcinogenesis in rats by TPA (12-0-tetradecanoyl-
phorbol-13-acetate). Cancer Res. 40: 4352-4355 (1980).
46. Topping, D. C., and Nettesheim, P Two-stage carcinogenesis
studies with asbestos in Fischer 344 rats. J. Natl. Cancer Inst.
65: 627-630 (1980).
47. Topping, D. C., Griesemer, R. A., and Nettesheim, P Quantita-
tive assessment of generalized epithelial changes in tracheal
mucosa following exposure to 7,12-dimethylbenz(a)anthracene.
Cancer Res. 39: 4823-4828 (1979).
48. Terzaghi, M., and Klein-Szanto, A. J. P Differentiation ofnormal
and cultured preneoplastic tracheal epithelial cells in rats: impor-
tance of epithelial-mesenchymal interactions. J. Natl. Cancer
Inst. 65: 1039-1048 (1980).
49. Klein-Szanto, A. J. P, and Terzaghi, M. Continuous propagation
of normal human respiratory epithelial cells using an in vivo
"culture system" an experimental model forthe study ofhuman
disease. Lab. Invest. 44: 34A (1981).
50. Terzaghi, M., Klein-Szanto, A. J. PC, and Shiba, M. An in
vivo-in vitro model for quantitative studies on the dynamics of
neoplastic development in human respiratory epithelium. Proc.
Am. Assoc. Cancer Res. 22: 135 (1981).